---
schema_version: "secwatch.filing_event.v1"
accession: "0001378325-26-000019"
form_type: "8-K"
ticker: "CV"
cik: "0001378325"
company_name: "CapsoVision, Inc"
filed_at: "2026-05-14T20:08:08+00:00"
generated_at: "2026-05-14T20:59:08.579308+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs

## Summary
- Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.
- Gross margin 48% vs 54% YoY due to impact of U.S. trade policies and tariffs.
- Operating expenses $8.4M, up $1.5M from CMOS sensor development with Canon and Colon clinical trials.
- Cash $17.9M; completed $14M PIPE financing on March 16, 2026.
- Pipeline: AI-assisted reading feature on track for mid-2026 FDA clearance; CapsoCam Colon 510(k) submission Q3 2026; pancreatic cancer study enrolled first patient May 2026.

## SEC filing metadata
- accession: 0001378325-26-000019
- form_type: 8-K
- ticker: CV
- cik: 0001378325
- company_name: CapsoVision, Inc
- filed_at: 2026-05-14T20:08:08+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/0001378325-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/cv-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001378325-26-000019
- JSON: https://secwatch.observer/filing/0001378325-26-000019.json
- Plain text: https://secwatch.observer/filing/0001378325-26-000019.txt

## Key facts
- Earnings Releases
  CapsoVision, Inc reported the fiscal quarter ended March 31, 2026 results: revenue $2.8 million.
  - Period: the fiscal quarter ended March 31, 2026
  - Revenue: $2.8 million
  - Result: reported results
  source text: and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights • Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025. • Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume
  evidence_url: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/0001378325-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.